Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
31/08/2026 11:31
BRIEF-Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN Aug 31 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:
PRELIM LOSS FOR THE YEAR A$18.8 MILLION
NO DIVIDENDS PAID OR DECLARED FOR YEAR ENDED JUNE 30, 2026
Further company coverage: CHM.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chimeric Therapeutics
See all newsBrief: Chimeric Therapeutics Says Phillip Hains Appointed Interim Chairman
Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
Brief: Chimeric Therapeutics Seeks Trading Halt
Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial